Clinical Trial Update: CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML [Phase 1]

View source ↗

Summary

Phase 1 trial of CD33KO-HSPC infusion followed by CART-33 infusion for refractory/relapsed acute myeloid leukemia is recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CART-33 infusion
• CD33KO-HSPC infusion

Snippet

Sponsor: University of Pennsylvania | Conditions: Leukemia, Myeloid, Acute | Phase 1 | Status: RECRUITING